Glaxo Wellcome Inc.

Burroughs Wellcome Co.

Alistair A Miller

Richard M Hyde

Malcolm Stuart Nobbs

Michael John Leach

Geoffrey Allan

Michael John

David A Sawyer

A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.

2-(n-alkylpiperazino or morpholino)-4-amino-5-aryl-pyrimidines

Pharmacologically active CNS compounds

Certain 2,4-diamino-5-(2,3-dihalophenyl)-6-substituted pyrimidines which

Certain 2,4-diamino-5-(2,3,5-TRI-chlorophenyl)-6-substituted-pyrimidines

Nitrile compounds

Compounds of Formula I are novel and useful as cardiovascular agents, particularly anti-arrhythmic agents: ##STR1## or the 5-imino-tautomer thereof or a salt of either, wherein R.sup.1 is C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl or C.sub.3-10 cycloalkyl, any of which is optionally substituted, and R.sup.2 to R.sup.6 are independently selected from hydrogen, halogen atom, C.sub.1-6 alkyl, alkenyl or alkynyl (all optionally substituted by one or more of halogen, hydroxy and aryl, amino, mono- or di-substituted amino, alkoxy (optionally substituted by one or more of halogen, hydroxy and aryl), alkenyloxy, aryl, acyloxy, cyano, nitro, aryl and alkylthio groups or any adjacent two of R.sup.2 to R.sup.6 are linked to form a (--CH.dbd.CH--CH.dbd.CH--) group.

1,2,4-triazines

Growing community of inventors

Beckenham, United Kingdom

Alistair A Miller